Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma

Nuclear Medicine Communications

Volumn 37, Issue 2, 2016, Pages 122-128

  Schmitt, Ronald J ^a   Kreidler, Sarah M ^b   Glueck, Deborah H ^b   Amaria, Rodabe N ^c   Gonzalez, Rene ^a   Lewis, Karl ^a   Bagrosky, Brian M ^a   Kwak, Jennifer J ^a   Koo, Phillip J ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Food Science and Human Nutrition   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

18F FDG; BRAF; Cobimetinib; Dabrafenib; MEK; Melanoma; PET CT; Trametinib; Vemurafenib

Indexed keywords

B RAF KINASE; COBIMETINIB; DABRAFENIB; FLUORODEOXYGLUCOSE F 18; MITOGEN ACTIVATED PROTEIN KINASE KINASE; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PROTEIN KINASE INHIBITOR;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME INHIBITION; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; MALE; METASTATIC MELANOMA; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PET-CT SCANNER; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; SHORT COURSE THERAPY; SURVIVAL RATE; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; DISEASE FREE SURVIVAL; GENETICS; MELANOMA; METASTASIS; MULTIMODAL IMAGING; MUTATION; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MAP KINASE KINASE KINASES; MELANOMA; MIDDLE AGED; MULTIMODAL IMAGING; MUTATION; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84953370728     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0000000000000406     Document Type: Article

References (28)

1. Higuchi M, Haseqawa T, Osugi J., Suzuki H, Gotoh M. Prognostic impact of FDG-PET in surgically treated pathologic stage I lung adenocarcinoma. Ann Thorac Cardiovasc Surg 2014; 20:185-191.
2. Berghmans T, Dusart M, Paesmans M., Hossein-Foucher C, Buvat I, Castaigne C., et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008; 3:6-12.
3. 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging in oncology: intial staging and evaluation of cancer therapy. Med Princ Pract 2013; 22:427-437.
4. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med 2010; 51:1337-1443.
5. Juweid ME. FDG-PET/CT in lymphoma. Methods Mol Biol 2011; 727:1-19.
6. Zanoni L, Cerci JJ, Fanti S. Use of PET/CT to evaluate response to therapy in lymphoma. J Nucl Med Mol Imaging 2011; 55:633-647.
7. Passero VA, Branstetter BF, Shuai Y, Heron D.E., Gibson MK, Lai SY, et al. Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy. Ann Oncol 2010; 21:2278-2283.
8. 18F] fluorodeoxyglucose. J Clin Oncol 2009; 27:535-541.
9. Martoni AA, Zamagni C, Quercia S., Rosati M, Cacciari N, Bernardi A., et al. Early (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy. Cancer 2010; 116:805-813.
10. Keam B, Im SA, Koh Y, Han S.W., Oh DY, Cho N, et al. Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC Cancer 2011; 11:452.
11. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. J Nucl Med 2012; 53:371-377.
12. Benz MR, Herrmann K, Walter F., Garon EB, Reckamp KL, Figlin R, et al (18) F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med 2011; 52:1684-1689.
13. 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clin Cancer Res 2011; 17:3304-3315.
14. 18 F-fluorothymidine PET. J Nucl Med 2011; 52:1871-1877.
15. Zander T, Scheffler M, Nogova L., Kobe C, Engel-Riedel W, Hellmich M, et al Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F] fluorothymidine positron emission tomography. J Clin Oncol 2011; 29:1701-1708.
16. 18F-FDG-PET/CT, CT, brain MRI, and tumor marker S-100B. Eur J Nucl Med Mol Imaging 2008; 35:1786-1795.
17. Beeram M, Patnaik A, Rowinsky EK Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005; 23:6771-6790.
18. Maldonado JL, Fridlyand J, Patel H., Jain AN, Busam K, Kageshita T, et al Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003; 95:1878-1890.
19. Lang J, Mackie RM Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J Invest Dermatol 2005; 125:575-579.
20. Curtin JA, Fridlyand J, Kageshita T., Patel HN, Busam KJ, Kutzner H, et al Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135-2147.
21. Chapman PB, Hauschild A, Robert C., Haanen JB, Ascierto P, Larkin J, et al Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
22. Solit DB, Garraway LA, Pratilas C.A., Sawai A., Getz G, Basso A, et al BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439: 358-362.
23. McArthur G, Puzanov I, Amaravadi R., Ribas A, Chapman P, Kim K.B., et al. Marked, homogenous, and early 18F fluorodeoxyglucose positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 2012; 30:1628-1634.
24. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35:1773-1782.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457.
26. Cox DR, Oakes D. Analysis of survival data. Boca Raton, FL: CRC Press; 1984.
27. V600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. EJNMMI Res 2012; 2:22.
28. Long GV, Stroyakovskiy D, Gogas H., Levchenko E, de Braud F, Larkin J, et al Combined BRAF and MEK inhibition versus BRAF inhibition alone in Melanoma. N Engl J Med 2014; 371:1877-1888.